Article: Eisai Enters into In-licensing Agreement with Sepracor for Eszopiclone Insomnia Treatment.

Tokyo, Japan, July 27, 2007 - (JCN Newswire) - Eisai Co., Ltd. and Sepracor Inc. signed an in-licensing agreement for the insomnia treatment eszopiclone (product name in the U.S.: LUNESTA(R)) on July 26, 2007 (the U.S. eastern time). In this agreement, Eisai will assume exclusive rights for development and marketing of this compound in Japan.

Eszopiclone is a non-benzodiazepine type allosteric GABA agonist discovered by Sepracor. With its short-acting feature that allows fewer interruptions during sleep, the compound may help patients with transient insomnia as well as chronic insomnia in the elderly. Furthermore, in clinical studies conducted in the U.S., the ...

Related newspaper, magazine, and journal articles:

 
 
Newsweek Harper's Magazine The Washington Post Chicago Tribune Crain's Chicago Business PRNewswire Pediatric News The Nation Advertising Age The Economist (US) A FREE trial gives you access to over 80 million articles! Access over 6,500 publications with a FREE trial!